RATIONALE: Chronic beryllium disease (CBD) is a CD4(+) T cell-mediated disorder characterized by persistent lung inflammation. Naturally occurring regulatory T (T(reg)) cells modulate adaptive immune responses. The role of this T-cell subset in beryllium-induced lung disease is unknown. OBJECTIVES: The aim of this study was to determine whether dysfunctional T(reg) cells in the lung contribute to the "unchecked" inflammatory response that characterizes CBD. METHODS: Using blood and bronchoalveolar lavage (BAL) cells from normal control subjects and individuals with beryllium-induced disease, we determined the frequency and function of naturally occurring T(reg) cells. MEASUREMENTS AND MAIN RESULTS: A significantly decreased percentage and expression of FoxP3 in BAL CD4(+) T cells from CBD patients compared with beryllium-sensitized subjects was seen, and the percentage of FoxP3-expressing CD4(+) T(reg) cells in BAL inversely correlated with disease severity. In contrast to blood T(reg) cells derived from beryllium-sensitized subjects and patients with CBD that completely suppressed blood responder T-cell proliferation, BAL FoxP3-expressing T(reg) cells from patients with CBD are unable to suppress anti-CD3-mediated BAL T-cell proliferation. Mixing studies showed that blood T(reg) cells are capable of suppressing autologous BAL responder T cells. Conversely, BAL CD4(+) T(reg) cells are incapable of suppressing blood T cells, confirming that the failure of BAL T(reg) cells to suppress T-cell proliferation is caused by a dysfunctional T(reg) cell subset and not by resistance of BAL effector T cells to suppression. CONCLUSIONS: These findings suggest that the deficient and dysfunctional T(reg) cells in the lung of patients with CBD contribute to the persistent inflammatory response in this disease.
RATIONALE: Chronic beryllium disease (CBD) is a CD4(+) T cell-mediated disorder characterized by persistent lung inflammation. Naturally occurring regulatory T (T(reg)) cells modulate adaptive immune responses. The role of this T-cell subset in beryllium-induced lung disease is unknown. OBJECTIVES: The aim of this study was to determine whether dysfunctional T(reg) cells in the lung contribute to the "unchecked" inflammatory response that characterizes CBD. METHODS: Using blood and bronchoalveolar lavage (BAL) cells from normal control subjects and individuals with beryllium-induced disease, we determined the frequency and function of naturally occurring T(reg) cells. MEASUREMENTS AND MAIN RESULTS: A significantly decreased percentage and expression of FoxP3 in BAL CD4(+) T cells from CBD patients compared with beryllium-sensitized subjects was seen, and the percentage of FoxP3-expressing CD4(+) T(reg) cells in BAL inversely correlated with disease severity. In contrast to blood T(reg) cells derived from beryllium-sensitized subjects and patients with CBD that completely suppressed blood responder T-cell proliferation, BAL FoxP3-expressing T(reg) cells from patients with CBD are unable to suppress anti-CD3-mediated BAL T-cell proliferation. Mixing studies showed that blood T(reg) cells are capable of suppressing autologous BAL responder T cells. Conversely, BAL CD4(+) T(reg) cells are incapable of suppressing blood T cells, confirming that the failure of BAL T(reg) cells to suppress T-cell proliferation is caused by a dysfunctional T(reg) cell subset and not by resistance of BAL effector T cells to suppression. CONCLUSIONS: These findings suggest that the deficient and dysfunctional T(reg) cells in the lung of patients with CBD contribute to the persistent inflammatory response in this disease.
Authors: Eric S Silverman; Lyle J Palmer; Venkat Subramaniam; Arlene Hallock; Sheeba Mathew; Joseph Vallone; Debora S Faffe; Toshiki Shikanai; Benjamin A Raby; Scott T Weiss; Stephanie A Shore Journal: Am J Respir Crit Care Med Date: 2003-11-03 Impact factor: 21.405
Authors: Yuji Miura; Christopher J Thoburn; Emilie C Bright; Michele L Phelps; Tahiro Shin; Elizabeth C Matsui; William H Matsui; Sally Arai; Ephraim J Fuchs; Georgia B Vogelsang; Richard J Jones; Allan D Hess Journal: Blood Date: 2004-06-01 Impact factor: 22.113
Authors: M D Rossman; J A Kern; J A Elias; M R Cullen; P E Epstein; O P Preuss; T N Markham; R P Daniele Journal: Ann Intern Med Date: 1988-05 Impact factor: 25.391
Authors: Michael G Risbano; Christina A Meadows; Christopher D Coldren; Tiffany J Jenkins; Michael G Edwards; David Collier; Wendy Huber; Douglas G Mack; Andrew P Fontenot; Mark W Geraci; Todd M Bull Journal: Clin Transl Sci Date: 2010-10 Impact factor: 4.689
Authors: Lisa A Maier; Briana Q Barkes; Margaret Mroz; Milton D Rossman; Juliana Barnard; May Gillespie; Allison Martin; Douglas G Mack; Lori Silveira; Richard T Sawyer; Lee S Newman; Andrew P Fontenot Journal: Respir Med Date: 2012-09-11 Impact factor: 3.415
Authors: Allison K Martin; Douglas G Mack; Michael T Falta; Margaret M Mroz; Lee S Newman; Lisa A Maier; Andrew P Fontenot Journal: J Allergy Clin Immunol Date: 2011-09-23 Impact factor: 10.793
Authors: C Preston Neff; Jennifer L Chain; Samantha MaWhinney; Allison K Martin; Derek J Linderman; Sonia C Flores; Thomas B Campbell; Brent E Palmer; Andrew P Fontenot Journal: Am J Respir Crit Care Med Date: 2015-02-15 Impact factor: 21.405
Authors: Douglas G Mack; Michael T Falta; Amy S McKee; Allison K Martin; Philip L Simonian; Frances Crawford; Terry Gordon; Robert R Mercer; Mark D Hoover; Philippa Marrack; John W Kappler; Rubin M Tuder; Andrew P Fontenot Journal: Proc Natl Acad Sci U S A Date: 2014-05-27 Impact factor: 11.205
Authors: Lori J Silveira; Matthew Strand; Michael V Van Dyke; Margaret M Mroz; Anna V Faino; Dana M Dabelea; Lisa A Maier; Tasha E Fingerlin Journal: PLoS One Date: 2017-11-16 Impact factor: 3.240